Titre : Fécondostimulants

Fécondostimulants : Questions médicales fréquentes

Termes MeSH sélectionnés :

Scleroderma, Diffuse
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Fécondostimulants : Questions médicales les plus fréquentes", "headline": "Fécondostimulants : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Fécondostimulants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-30", "dateModified": "2025-02-24", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Fécondostimulants" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Agents régulateurs de la reproduction", "url": "https://questionsmedicales.fr/mesh/D012102", "about": { "@type": "MedicalCondition", "name": "Agents régulateurs de la reproduction", "code": { "@type": "MedicalCode", "code": "D012102", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.954.705" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Fécondostimulants féminins", "alternateName": "Fertility Agents, Female", "url": "https://questionsmedicales.fr/mesh/D005300", "about": { "@type": "MedicalCondition", "name": "Fécondostimulants féminins", "code": { "@type": "MedicalCode", "code": "D005300", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.954.705.552.344" } } }, { "@type": "MedicalWebPage", "name": "Fécondostimulants masculins", "alternateName": "Fertility Agents, Male", "url": "https://questionsmedicales.fr/mesh/D005303", "about": { "@type": "MedicalCondition", "name": "Fécondostimulants masculins", "code": { "@type": "MedicalCode", "code": "D005303", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.954.705.552.510" } } } ], "about": { "@type": "MedicalCondition", "name": "Fécondostimulants", "alternateName": "Fertility Agents", "code": { "@type": "MedicalCode", "code": "D005299", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "N Chabbert-Buffet", "url": "https://questionsmedicales.fr/author/N%20Chabbert-Buffet", "affiliation": { "@type": "Organization", "name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France. Electronic address: nathalie.chabbert-buffet@aphp.fr." } }, { "@type": "Person", "name": "N Sermondade", "url": "https://questionsmedicales.fr/author/N%20Sermondade", "affiliation": { "@type": "Organization", "name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France." } }, { "@type": "Person", "name": "E Moreau", "url": "https://questionsmedicales.fr/author/E%20Moreau", "affiliation": { "@type": "Organization", "name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France." } }, { "@type": "Person", "name": "S Cristofari", "url": "https://questionsmedicales.fr/author/S%20Cristofari", "affiliation": { "@type": "Organization", "name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France." } }, { "@type": "Person", "name": "N Johnson", "url": "https://questionsmedicales.fr/author/N%20Johnson", "affiliation": { "@type": "Organization", "name": "Centre de fertilité Tenon, hôpital Tenon, Sorbonne université, AP-HP, Paris, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The association of IL-33 and systemic sclerosis: a systematic review and meta-analysis.", "datePublished": "2022-10-28", "url": "https://questionsmedicales.fr/article/36306005", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12026-022-09329-1" } }, { "@type": "ScholarlyArticle", "name": "Spectrum of renal disease in scleroderma other than scleroderma renal crisis: A review of the literature.", "datePublished": "2024-05-03", "url": "https://questionsmedicales.fr/article/38699985", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.5414/CN111243" } }, { "@type": "ScholarlyArticle", "name": "Myositis mimics in scleroderma: A case series of neuromuscular diseases that can co-exist in scleroderma.", "datePublished": "2023-09-18", "url": "https://questionsmedicales.fr/article/38333529", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/23971983231197442" } }, { "@type": "ScholarlyArticle", "name": "Effect of pregnancy on scleroderma progression.", "datePublished": "2022-06-19", "url": "https://questionsmedicales.fr/article/36743807", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/23971983221101311" } }, { "@type": "ScholarlyArticle", "name": "Reference value for the 6-min walking distance in women with systemic sclerosis considering the impact of muscle strength.", "datePublished": "2023-09-15", "url": "https://questionsmedicales.fr/article/37725867", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clinbiomech.2023.106094" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Utilisations thérapeutiques", "item": "https://questionsmedicales.fr/mesh/D045506" }, { "@type": "ListItem", "position": 5, "name": "Agents régulateurs de la reproduction", "item": "https://questionsmedicales.fr/mesh/D012102" }, { "@type": "ListItem", "position": 6, "name": "Fécondostimulants", "item": "https://questionsmedicales.fr/mesh/D005299" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Fécondostimulants - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Fécondostimulants", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Fécondostimulants", "description": "Comment diagnostiquer l'infertilité ?\nQuels tests pour évaluer la réserve ovarienne ?\nQuand consulter un spécialiste de la fertilité ?\nQuels signes indiquent un problème d'ovulation ?\nComment évaluer la qualité du sperme ?", "url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Scleroderma,+Diffuse&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Fécondostimulants", "description": "Quels symptômes d'infertilité chez la femme ?\nQuels signes d'infertilité chez l'homme ?\nComment reconnaître un déséquilibre hormonal ?\nQuels symptômes d'ovulation irrégulière ?\nQuels symptômes d'une maladie des ovaires ?", "url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Scleroderma,+Diffuse&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Fécondostimulants", "description": "Comment prévenir l'infertilité ?\nQuel rôle de l'alimentation sur la fertilité ?\nComment le stress affecte-t-il la fertilité ?\nPourquoi éviter les toxines environnementales ?\nQuel impact de l'âge sur la fertilité ?", "url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Scleroderma,+Diffuse&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Fécondostimulants", "description": "Quels sont les principaux fécondostimulants ?\nComment fonctionne le clomifène ?\nQuand utiliser des gonadotrophines ?\nQuels effets secondaires des fécondostimulants ?\nComment se déroule une stimulation ovarienne ?", "url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Scleroderma,+Diffuse&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Fécondostimulants", "description": "Quelles complications des fécondostimulants ?\nComment reconnaître le syndrome d'hyperstimulation ?\nQuels risques de grossesses multiples ?\nQuelles sont les conséquences d'une grossesse multiple ?\nQuels effets à long terme des fécondostimulants ?", "url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Scleroderma,+Diffuse&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Fécondostimulants", "description": "Quels facteurs de risque d'infertilité ?\nQuel impact des antécédents familiaux ?\nComment le poids influence-t-il la fertilité ?\nQuel rôle des maladies chroniques ?\nComment l'environnement influence-t-il la fertilité ?", "url": "https://questionsmedicales.fr/mesh/D005299?mesh_terms=Scleroderma,+Diffuse&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer l'infertilité ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'infertilité se diagnostique par des tests hormonaux, échographies et analyses de sperme." } }, { "@type": "Question", "name": "Quels tests pour évaluer la réserve ovarienne ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par la mesure de l'hormone antimüllérienne (AMH) et l'échographie." } }, { "@type": "Question", "name": "Quand consulter un spécialiste de la fertilité ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Il est conseillé de consulter après un an d'essais infructueux pour les couples de moins de 35 ans." } }, { "@type": "Question", "name": "Quels signes indiquent un problème d'ovulation ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des cycles irréguliers, des règles absentes ou des douleurs pelviennes peuvent indiquer un problème." } }, { "@type": "Question", "name": "Comment évaluer la qualité du sperme ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La qualité du sperme est évaluée par une analyse de sperme, mesurant la concentration et la motilité." } }, { "@type": "Question", "name": "Quels symptômes d'infertilité chez la femme ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des cycles irréguliers, des douleurs pelviennes et des règles absentes." } }, { "@type": "Question", "name": "Quels signes d'infertilité chez l'homme ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les signes peuvent inclure des problèmes d'érection, des douleurs testiculaires ou des anomalies du sperme." } }, { "@type": "Question", "name": "Comment reconnaître un déséquilibre hormonal ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme l'acné, la prise de poids ou des changements d'humeur peuvent indiquer un déséquilibre." } }, { "@type": "Question", "name": "Quels symptômes d'ovulation irrégulière ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des cycles menstruels irréguliers et des douleurs pelviennes peuvent signaler une ovulation irrégulière." } }, { "@type": "Question", "name": "Quels symptômes d'une maladie des ovaires ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs pelviennes, des règles irrégulières et des problèmes de fertilité." } }, { "@type": "Question", "name": "Comment prévenir l'infertilité ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un poids santé, éviter le tabac et gérer le stress peuvent aider à prévenir l'infertilité." } }, { "@type": "Question", "name": "Quel rôle de l'alimentation sur la fertilité ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée riche en antioxydants et en acides gras oméga-3 peut améliorer la fertilité." } }, { "@type": "Question", "name": "Comment le stress affecte-t-il la fertilité ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut perturber les cycles hormonaux et affecter l'ovulation, réduisant ainsi la fertilité." } }, { "@type": "Question", "name": "Pourquoi éviter les toxines environnementales ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Les toxines peuvent nuire à la qualité du sperme et à la santé reproductive, augmentant le risque d'infertilité." } }, { "@type": "Question", "name": "Quel impact de l'âge sur la fertilité ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "L'âge avancé réduit la qualité des ovules et la fertilité, surtout après 35 ans chez les femmes." } }, { "@type": "Question", "name": "Quels sont les principaux fécondostimulants ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux fécondostimulants incluent le clomifène, les gonadotrophines et l'acide folique." } }, { "@type": "Question", "name": "Comment fonctionne le clomifène ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Le clomifène stimule l'ovulation en bloquant les récepteurs d'œstrogènes dans l'hypothalamus." } }, { "@type": "Question", "name": "Quand utiliser des gonadotrophines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les gonadotrophines sont utilisées lorsque le clomifène est inefficace ou en cas d'infertilité sévère." } }, { "@type": "Question", "name": "Quels effets secondaires des fécondostimulants ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure des bouffées de chaleur, des nausées et des douleurs abdominales." } }, { "@type": "Question", "name": "Comment se déroule une stimulation ovarienne ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La stimulation ovarienne implique des injections de médicaments et un suivi échographique régulier." } }, { "@type": "Question", "name": "Quelles complications des fécondostimulants ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure le syndrome d'hyperstimulation ovarienne et des grossesses multiples." } }, { "@type": "Question", "name": "Comment reconnaître le syndrome d'hyperstimulation ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs abdominales, des nausées et un gain de poids rapide après traitement." } }, { "@type": "Question", "name": "Quels risques de grossesses multiples ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les fécondostimulants augmentent le risque de grossesses multiples, ce qui peut entraîner des complications." } }, { "@type": "Question", "name": "Quelles sont les conséquences d'une grossesse multiple ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les grossesses multiples peuvent entraîner des naissances prématurées et des complications pour la mère." } }, { "@type": "Question", "name": "Quels effets à long terme des fécondostimulants ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les effets à long terme peuvent inclure des risques accrus de cancer ovarien, bien que les données soient limitées." } }, { "@type": "Question", "name": "Quels facteurs de risque d'infertilité ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, des antécédents médicaux, le tabagisme et l'obésité." } }, { "@type": "Question", "name": "Quel impact des antécédents familiaux ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents familiaux d'infertilité peuvent augmenter le risque d'infertilité chez les individus." } }, { "@type": "Question", "name": "Comment le poids influence-t-il la fertilité ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Un poids excessif ou insuffisant peut perturber les cycles hormonaux et affecter la fertilité." } }, { "@type": "Question", "name": "Quel rôle des maladies chroniques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des maladies comme le diabète ou le syndrome des ovaires polykystiques peuvent affecter la fertilité." } }, { "@type": "Question", "name": "Comment l'environnement influence-t-il la fertilité ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "L'exposition à des produits chimiques et à des toxines peut nuire à la qualité reproductive." } } ] } ] }

Sources (8700 au total)

Spectrum of renal disease in scleroderma other than scleroderma renal crisis: A review of the literature.

Systemic sclerosis (SSc) is a multi-system rheumatic disease characterized by vascular and fibrotic manifestations that can affect practically every organ. Scleroderma renal crisis (SRC) is the most c... A literature search was conducted on PubMed and Cochrane from inception to December 2022 using medical subject headings (MeSH) terms for "scleroderma", "systemic sclerosis" combined with "renal injury... The initial search revealed 393 articles. After the exclusion of duplicates and non-relevant articles, data was included from 30 articles and 45 patients. The mean age was 55.2 years, 9 males (20%) an... The spectrum of kidney involvement in SSc can range from asymptomatic reduction of the glomerular filtration rate to life-threatening scleroderma renal crisis. Therefore, it is essential that physicia...

Effect of pregnancy on scleroderma progression.

To explore the trajectory of scleroderma disease activity in women who experienced a pregnancy after systemic sclerosis diagnosis compared to nulliparous women.... We analyzed data from the Canadian Scleroderma Research Group registry by identifying nulliparous women and women with ⩾1 pregnancy after systemic sclerosis diagnosis. Patient characteristics were com... At registry entry, numbers of women in the nulliparous and pregnancy after systemic sclerosis diagnosis groups were 153 and 45, respectively. Corresponding numbers at 6 and 9 years were 48 and 21, and... Results demonstrated that having ⩾1 pregnancy after systemic sclerosis diagnosis did not appear to significantly impact long-term renal, respiratory, or global function outcomes. While this offers a h...

Reference value for the 6-min walking distance in women with systemic sclerosis considering the impact of muscle strength.

Early triage, the search for new therapies, and closer monitoring of patients with systemic sclerosis before their lung function irreversibly deteriorates are urgent concerns. Because it is an indepen... This was a cross-sectional study in which 69 women with systemic sclerosis underwent the 6-min walk test, Health Assessment Questionnaire-Disability Index, pulmonary function, handgrip strength test, ... The mean 6-min walking distance was 447 ± 78 m, and 43.5% of the participants did not reach 80% of their predicted value. 6-min walking distance correlated positively with quadriceps strength (r = 0.4... Muscle function and, to a lesser extent, lung function are key contributors in determining the reference value for the 6-min walking distance in women with diffuse cutaneous systemic sclerosis-associa...

Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registry.

Current recommendations on the management of systemic sclerosis (SSc) suggest that autologous hematopoietic stem cell therapy (HSCT) can be a rescue therapy for patients with rapidly progressive SSc.... To assess the safety and efficacy of HSCT for patients with SSc and to compare these with non-HSCT patients in a control cohort with adjusted risk factors.... A retrospective analysis of data from the multicentric German network for systemic scleroderma (DNSS) with 5000 patients with SSc. Control groups consisted of all patients with diffuse cutaneous (dc)-... Eighty SSc patients received an HSCT 4.1 ± 4.8 years after SSc diagnosis. Among them, 86.3% had dc-SSc, 43.5% were males, and 71.3% were positive for Scl70 antibodies. The control group A (n=1513) sho... Our analysis of real-life data show that the distribution of risk factors for mortality is critical when HSCT cohorts are compared with non-HSCT control groups....

Systemic sclerosis in Native Americans of the American Southwest.

Many indigenous non-Caucasian populations, including Native Americans, have been reported to have higher rates, distinct clinical phenotypes, increased complications, and greater severity of systemic ... This cross-sectional retrospective study included 137 SSc patients (109 [80%] were non-Native and 28 [20%] were Native Americans) followed over a mean of 11.5 ± 7.6 years. Participants were repetitive... The estimated prevalence of SSc in Native Americans was 40.0 cases/100 000 vs 17.1 cases/100 000 for non-Natives (odds ratio 2.34, 95% confidence interval [CI] 1.55-3.55, P < .001). The cohorts were s... In Native Americans of the American Southwest, SSc is increased in prevalence but is phenotypically similar to SSc in non-Natives. However, mortality due specifically to infection is increased in Nati...

Scleroderma-overlap syndromes: capillaroscopy, laboratory, and clinical manifestations and follow-up compared to scleroderma patients.

Overlap syndrome (OS) is a group of systemic connective tissue diseases (CTDs) that meet the criteria of two or more CTDs. In this study, we evaluated clinical, laboratory, and capillaroscopic manifes... In a 10-year cross-sectional study, we evaluated 135 adult patients (70 with SSc-OS and 65 with LcSSc) with the same skin score for their baseline and follow-up clinical, laboratory, high-resolution c... Of the 135 patients, 70 had SSc-OS, including 45 (64.3%) cases of SSc-SS (Sjögren's syndrome), 11 (15.7%) of SSc-RA (rheumatoid arthritis), 9 (12.9%) of SSc-myositis and 5 (1.7%) of SSc-SLE (systemic ... In SSc-OS patients, the most common subgroup was SSc-SS. Scleroderma OS was associated with lower major organ involvement and capillaroscopy progression than LcSSc. Major organ involvement in patients...

Capturing the Range of Disease Involvement in Localized Scleroderma: The Localized scleroderma Total Severity Scale (LoTSS).

Juvenile localized scleroderma (jLS) is a chronic autoimmune disease commonly associated with poor outcome, including contractures, hemi-atrophy, uveitis, and seizures. Despite improvements in treatme... LoTSS was developed as a weighted measure by a consensus process involving literature review, surveys, case vignettes, and multi-criteria decision analysis. Feasibility was assessed in larger Childhoo... LoTSS severity items were organized into modules that reflect jLS disease patterns, with modules for skin, extracutaneous, and craniofacial manifestations. Construct validity of LoTSS was supported by... We developed a new LS measure for assessing cutaneous and extracutaneous severity, and have shown it to be reliable, valid, and responsive. LoTSS is the first measure that assesses and scores all the ...